2. UroToday Home
  3. Actionable Clinical Data
  4. Risk-Stratified NMIBC Management
  5. Articles
  6. Conferences

SUO 2023

SUO 2023

SUO 2023: Joseph A. Smith, Jr. Mentorship Award Lecture: Take Inventory, Embrace Failure, Move Forward, and Be Grateful

Details
(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to the annual Joseph A. Smith, Jr. Mentorship Award Lecture delivered this year by the awardee Dr. Robert Uzzo, entitled: “Take Inventory, Embrace Failure, Move Forward, and Be Grateful.”

SUO 2023: Novel and Approaches in Renal Cell Carcinoma

Details
(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to a kidney cancer session. Dr. Ulka Vaishampayan presented novel and upcoming therapies in renal cell carcinoma (RCC). These approaches include targeted and immune therapies, as well as antibody drug conjugates:

SUO 2023: Evolution of the Urologic Oncologist

Details

(UroToday.com) At the 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, Dr. Michael Cookson was honored with the prestigious Huggins Medal award.

SUO 2023: Decipher® Genomic Classifier on Initial Prostate Biopsy is Associated with Gleason Score Upgrading on Final Radical Prostatectomy Pathology

Details

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. John Sheng discussing the influence of the Decipher® genomic classifier on initial prostate biopsy Gleason Score upgrading on final radical prostatectomy pathology. Traditionally, PSA has been used to screen for prostate cancer. However, the utility of PSA has become controversial due to poor diagnostic accuracy. As such, other clinical tools such as prostate multiparametric MRI and genomic classifiers like Decipher® genomic classifier are recommended to risk stratify newly diagnosed prostate cancer patients in the pre-treatment setting. While multiparametric MRI, and the Prostate Imaging-Reporting and Data System (PI-RADS), are considered predictive of prostatectomy pathology, Decipher® genomic classifier has been shown to independently predict adverse pathology in patients with prostate cancer. The objective of this study presented at the SUO 2023 annual meeting was to examine the relationship between pre-treatment Decipher® and multiparametric MRI on prostatectomy pathology.

SUO 2023: Optimizing Care for Women: Gynecologic Considerations for the Urologic Oncologist

Details

(UroToday.com) The 2023 SUO annual meeting included a state of the art lecture by Dr. Ariana Smith discussing gynecologic considerations for the urologic oncologist and optimizing care for women. Dr. Smith noted that the main learning objectives for her talk are to emphasize assessment of the cervix, assessment of the uterus, and management of the adnexa.

SUO 2023: Long-term Outcomes of Bladder-Sparing Therapy Compared to Upfront Radical Cystectomy in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in an International Cohort

Details

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to the Young Urologic Oncologists (YUO) program. Dr. Jacob Taylor presented the long-term results of a comparative analysis of bladder-sparing therapy versus upfront radical cystectomy in an international cohort of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

SUO 2023: Factors Associated with PSMA Positivity at Low PSA After Radical Prostatectomy

Details

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Eric Li discussing factors associated with PSMA positivity at low PSA after radical prostatectomy. PSMA-based imaging is the preferred imaging modality recommended by NCCN guidelines for work-up of suspected recurrent or persistent prostate cancer after initial treatment with radical prostatectomy or prostate radiation and is increasingly being utilized in clinical practice.

SUO 2023: Decipher® Genomic Classifier Score on Initial Biopsy is Associated with Progression from Active Surveillance to Treatment in Prostate Cancer

Details

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Nimrod Barashi discussing the association of the Decipher® genomic classifier on initial prostate biopsy and progression from active surveillance to treatment. Active surveillance is currently the recommended treatment for very low- and low-risk prostate cancer and is also being more frequently used for favorable intermediate risk prostate cancer in select patients.

SUO 2023: Systemic Therapy: Choosing Among Neoadjuvant/adjuvant Approaches for Upper Tract Urothelial Carcinoma

Details

(UroToday.com) The 2023 SUO annual meeting included a session on urothelial cancer, featuring a presentation by Dr. Jean Hoffman-Censits discussing choosing among neoadjuvant or adjuvant approaches for systemic therapy. Dr. Hoffman-Censits started by summarizing the two prospective neoadjuvant cisplatin trials.

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

Details
Reno, Nevada (UroToday.com) -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that new evidence from routine clinical practice in the Veterans Affairs (VA) healthcare system was presented at the 24th Annual Society of Urologic Oncology (SUO) meeting demonstrating a significantly reduced risk of tumor recurrence (33%) in non-muscle invasive bladder cancer (NMIBC) patients who received Blue Light Cystoscopy (BLC®) compared to patients who only underwent standard White Light Cystoscopy (WLC).

SUO 2023: Grade and Volume Progression and Its Association with the Decipher® Genomic Classifier Using Patients Enrolled in a Prospective Active Surveillance Protocol

Details

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Archan Khandekar discussing grade and volume progression and its association with the Decipher® genomic classifier using patients enrolled in a prospective active surveillance protocol.

SUO 2023: SWOG 2210: Neoadjuvant Carboplatin for High-Risk Localized Prostate Cancer with Germline BRCA1/2 Mutations

Details

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, hosted a prostate cancer session. Dr. Heather Cheng presented the SWOG 2210 trial of neoadjuvant carboplatin for patients with high-risk, localized prostate cancer and germline BRCA1/2 mutations.

SUO 2023: From Incision to Intervals: Fine-Tuning Uro-Oncological Follow-Up

Details

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to the annual European Association of Urology (EAU) lecture presented by Dr. Christian Fankhauser, entitled: “From Incision to Intervals: Fine-Tuning Uro-oncological Follow-Up”.

SUO 2023: Defining the Biology of Upper Tract Urothelial Carcinoma and How This Shapes Therapy

Details

(UroToday.com) The 2023 SUO annual meeting included a session on urothelial cancer, featuring a presentation by Dr. Bishoy Faltas discussing the biology of upper tract urothelial carcinoma and how it shapes therapy. Dr. Faltas started by highlighting that upper tract urothelial carcinoma makes up 5-10% of all urothelial carcinomas, and has a unique epidemiologic association with arsenic exposure and aristolochic acid. Additionally, upper tract urothelial carcinoma presents with muscle invasion (pT2+) in 60% of cases versus 20-30% of bladder cancers. Upper tract urothelial carcinoma has more advanced disease at presentation, but similar outcomes as bladder cancer after controlling for stage.

SUO 2023: Trials in Upper Tract Urothelial Carcinoma and Unmet Needs

Details

(UroToday.com) The 2023 SUO annual meeting included a session on urothelial cancer, featuring a presentation by Dr. Jennifer Linehan discussing trials in upper tract urothelial carcinoma and unmet needs. Dr. Linehan started her presentation with a great summary slide of the current upper tract urothelial carcinoma trials delineated by disease space:

SUO 2023: FALCON: Gaining Consensus on Focal Therapy for Localized Prostate Cancer

Details

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to the Confederación Americana de Urología (CAU) session. Dr. Lara Rodríguez Sánchez presented the Falcon Project which aims to reach a consensus on focal therapy usage in prostate cancer patients.

SUO 2023: NePtune - A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Details

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host a prostate cancer session. Dr. Rana McKay presented the NePtune trial, a phase 2 study of neoadjuvant PARP inhibition plus androgen deprivation therapy (ADT) followed by radical prostatectomy in patients with unfavorable intermediate- or high-risk prostate cancer with BRCA1/2 gene alterations

SUO 2023: Drug Costs and Pricing Highlights from the Health Policy Poster Session

Details

(UroToday.com) During the Society of Urologic Oncology Annual Meeting in Washington, DC, several health policy posters were presented exploring the integral issue of financial toxicity in the care of urologic cancers. Dr. Benjamin Pockros from the University of Michigan presented a study, recently published in Urology Practice, exploring the impact of recent legislation on drug costs for prostate cancer patients.

SUO 2023: Primary Chemoablation for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer: The ENVISION Trial

Details

(UroToday.com) The 2023 SUO annual meeting included a late breaking abstract session on urothelial cancer, featuring a presentation by Dr. Sandip Prasad discussing results from the ENVISION trial assessing primary chemoablation for recurrent low grade intermediate risk non-muscle invasive bladder cancer. Low grade intermediate risk non-muscle invasive bladder cancer includes patients who have one or two of the following:

SUO 2023: First Results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC

Details

(UroToday.com) The 2023 SUO annual meeting included a late breaking abstract session on urothelial cancer, featuring a presentation by Dr. Mark Tyson discussing the first results of BOND-003, a phase 3 study of intravesical Cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG- unresponsive NMIBC.